EQL Pharma AB (OSTO:EQL) Total Equity: kr267.1 Mil (As of Mar. 2026)


OSTO:EQL EQL Pharma AB OSTO:EQL
42 GF Score
Price kr23.15
! 4 Warning Signs
View Full Analysis

What is EQL Pharma AB Total Equity?

EQL Pharma AB OSTO:EQL -2.32% 42 Total Equity is kr267.1 Mil as of Mar. 2026. GuruFocus rates OSTO:EQL with a GF Score™ of 42/100. The stock has 4 warning signs investors should review.

EQL Pharma AB's total equity for the quarter that ended in Mar. 2026 was kr267.1 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

EQL Pharma AB Total Equity Historical Data

* Premium members only.

The historical data trend for EQL Pharma AB's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

EQL Pharma AB Total Equity Chart

EQL Pharma AB Annual Data
Trend Dec16 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 123.63 154.75 177.73 221.03 267.06

EQL Pharma AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 221.03 230.87 260.00 269.78 267.06
OSTO:EQL
42GF Score
EQL Pharma AB OSTO:EQL
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

EQL Pharma AB Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

EQL Pharma AB's Total Equity for the fiscal year that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=850.887-583.831
=267.1

EQL Pharma AB's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=850.887-583.831
=267.1

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of kr267.1 Mil mean?
EQL Pharma AB (OSTO:EQL) has a Total Equity of kr267.1 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for EQL Pharma AB and its competitors.
Is EQL Pharma AB's Total Equity too high?
EQL Pharma AB's current Total Equity is kr267.1 Mil. Overall, EQL Pharma AB has a GF Score™ of 42/100, reflecting its overall financial health beyond just this single metric.
How does EQL Pharma AB's Total Equity compare to ZTS and UTHR?
EQL Pharma AB's Total Equity of kr267.1 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Drug Manufacturers company?
A good Total Equity depends on the Drug Manufacturers industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for EQL Pharma AB and its competitors. EQL Pharma AB's current Total Equity is kr267.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is EQL Pharma AB stock overvalued right now?
EQL Pharma AB (OSTO:EQL) has a current Total Equity of kr267.1 Mil. The current Total Equity is kr267.1 Mil. EQL Pharma AB's overall GF Score™ is 42/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For EQL Pharma AB (OSTO:EQL), the current Total Equity is kr267.1 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

EQL Pharma AB Business Description

Other Exchanges 7JK:Germany
Address Stortorget 1, 3rd Floor, Lund, SWE, 222 23
EQL Pharma AB is a pharmaceutical company focused on efficiently and thoughtfully developing and marketing generic drugs. The company operates in one segment, which is medicine. Its niche generics are divided into four parts based on four sales and marketing models: Retail, Hospital, Branded, and Tests. EQL Pharma specializes in identifying, developing, and selling generics, i.e., medicines that are medically equivalent to originator medicines. The company operates in Sweden, Denmark, Norway, Finland, the rest of Europe, and outside Europe, generating the majority of its revenue from Sweden.
42GF Score

Get the complete analysis for OSTO:EQL

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr23.15
Price